The fund fully exited its Compass stake, which had previously represented 4.3% of its 13F assets under management (AUM) as of the prior quarter. Top holdings after the filing: NYSE:SNAP: $8.83 million ...

Compass, America's biggest real estate broker, is declaring victory over Zillow as the home search giant tries a new tactic after listings ban.

Psychedelic drug developer Compass Pathways is preparing to talk to the FDA about filing its psilocybin therapy COMP360 for approval in treatment-resistant depression (TRD), after reporting positive ...

Independent computer analysts are on high alert. With the spread of artificial intelligence, the risks to our privacy are ...

COMPASS identifies and removes stones, sticks, plastic, metal and extraneous vegetable matter, as well as discolored or ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced that tomorrow it will report new clinical data from two ...

Investing.com - William Blair reiterated an Outperform rating on Compass Therapeutics (NASDAQ:CMPX) on Thursday as the company reported fourth-quarter earnings and provided a business update. The ...

Compass Therapeutics, Inc. is set to report fourth-quarter and full-year 2025 results on Friday, with investors focused less on the biotech’s expected loss and more on progress toward a potential ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Good morning. I’ve fallen ...

The American Depositary Shares ("ADS") of the United Kingdom-based biotech Compass Pathways plc (CMPS) are soaring today, after management announced its psychedelic drug candidate COMP006 had met the ...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced that tomorrow it will ...